4 results on '"Erica Scalambrino"'
Search Results
2. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection
- Author
-
Sophie Testa, Oriana Paoletti, Marigrazia Clerici, Armando Tripodi, Veena Chantarangkul, Cristina Novembrino, Flora Peyvandi, Massimo Boscolo-Anzoletti, and Erica Scalambrino
- Subjects
medicine.medical_specialty ,Pyridones ,Administration, Oral ,030204 cardiovascular system & hematology ,Gastroenterology ,Dabigatran ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Rivaroxaban ,Edoxaban ,Internal medicine ,medicine ,Humans ,Lead (electronics) ,Lupus anticoagulant ,business.industry ,Anticoagulants ,Atrial fibrillation ,Hematology ,Antiphospholipid Syndrome ,medicine.disease ,Silica clotting time ,chemistry ,Lupus Coagulation Inhibitor ,030220 oncology & carcinogenesis ,Apixaban ,business ,medicine.drug - Abstract
Background Lupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral anticoagulants (DOAC) that may lead to false-positive results. Aims We aimed to investigate the effect of a commercially available DOAC absorbent on residual drug concentrations, and on integrated procedures for LA-detection. Methods Blood from patients treated for atrial fibrillation with either dabigatran (n = 39), rivaroxaban (n = 55), apixaban (n = 47) or edoxaban (n = 47) were collected at peak and trough, and centralized for testing with two LA integrated procedures [i.e., the silica clotting time (SCT) and dilute Russel viper venom (dRVVT)] before and after DOAC absorbent exposure. Results The commercially available DOAC absorbent investigated in this study proved effective in reducing the concentrations of all the investigated DOAC, although small residual drug was detected after absorption, especially in patients on edoxaban. Results mimicking LA were observed in patients on DOAC before absorbent exposure, especially for rivaroxaban when testing was performed with dRVVT (88% rate at peak and 20% at trough) and much less with SCT (12% at peak and 8% at trough). The correspondent rate of results mimicking LA in patients on rivaroxaban after exposure was reduced [dRVVT (peak 8%, trough 4%); SCT (peak and trough 8%)], but not abolished. Conclusions Overall, in vitro DOAC absorbance by active charcoal compounds is a useful laboratory tool for LA-detection in patients on DOAC. Caution should however be exerted when used in daily practice.
- Published
- 2021
3. Procoagulant imbalance in preterm neonates detected by thrombin generation procedures
- Author
-
Giacomo Cavallaro, Stefano Ghirardello, Lidia Padovan, Flora Peyvandi, Marigrazia Clerici, Armando Tripodi, Fabio Mosca, Erica Scalambrino, Genny Raffaeli, and Veena Chantarangkul
- Subjects
medicine.medical_specialty ,030204 cardiovascular system & hematology ,Thrombin generation ,03 medical and health sciences ,0302 clinical medicine ,Coagulopathy ,medicine ,Humans ,Blood Coagulation ,Obstetrics ,business.industry ,Infant, Newborn ,Thrombin ,Infant ,Gestational age ,Hematology ,medicine.disease ,Low birth weight ,Coagulation ,030220 oncology & carcinogenesis ,Prothrombin Time ,Partial Thromboplastin Time ,Blood Coagulation Tests ,Fresh frozen plasma ,medicine.symptom ,business - Abstract
Preterm newborns are considered at risk of acquired coagulopathy and are often prophylactically infused with fresh frozen plasma (FFP) even in the absence of bleeding. To assess the coagulation asset of preterm neonates and the biological plausibility of such infusions, we investigated at birth 87 very low birth weight (≤1500 g) preterm (gestational age35 weeks) newborns and 64 full-term newborns. Preterm neonates were also investigated at different time-points up to 30 days after birth. Plasma from preterm and full-term neonates were subjected to the measurement of prothrombin and activated partial thromboplastin time (PT, APTT), pro- and anticoagulant factors as well as to thrombin-generation procedures both with and without thrombomodulin. PT and APTT of preterm newborns were longer than those of full-term neonates [PT: 15.9 s (11.7-51.2)-vs-13.8 (11.0-25.4), p 0.001. APTT: 59.0 (37.8-97.5)-vs- 47.3 (28.1-71.9), p 0.001] and tended to shortening after 30 days from birth. Thrombin-generation defined as endogenous thrombin potential (ETP) was increased in preterm as compared to full-term neonates at birth [1322 nM·min (474-2384)-vs-1006 (697-1612), p 0.001] and did not change appreciably over time up to 30 days from birth. In conclusion, plasma from preterm neonates displays a procoagulant imbalance at birth as shown by increasing ETP, despite the prolongation of PT and APTT. The results define preterm newborns as having hyper- rather than hypo-coagulability and argue against the infusion of FFP when given prophylactically and/or based solely on prolongation of PT or APTT.
- Published
- 2020
4. How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters
- Author
-
Erica Scalambrino, Armando Tripodi, Sophie Testa, Lidia Padovan, Flora Peyvandi, and Chantarangkul Veena
- Subjects
Time Factors ,medicine.drug_mechanism_of_action ,Pyridones ,Thrombomodulin ,Factor Xa Inhibitor ,Administration, Oral ,Pharmacology ,Thrombin ,medicine ,Humans ,Blood Coagulation ,Blood coagulation test ,Prothrombin time ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,Chemistry ,Anticoagulants ,Hematology ,Coagulation ,Anesthesia ,Prothrombin Time ,Pyrazoles ,Partial Thromboplastin Time ,Apixaban ,Blood Coagulation Tests ,Factor Xa Inhibitors ,circulatory and respiratory physiology ,medicine.drug ,Partial thromboplastin time - Abstract
Background and objectives Apixaban is a direct oral anticoagulant (DOAC) targeting factor Xa and thus quenching thrombin generation and clot formation. However, little information is available on the influence that apixaban may have on the parameters of thrombin generation. Methods Aliquots of a pooled normal plasma have been added with increased concentrations of purified apixaban and were used to assess the degree of modification brought about by the drug on the basic tests of coagulation prothrombin and activated partial thromboplastin time (PT and APTT) and on thrombin generation parameters. Results The study shows that while apixaban has little effect on PT or APTT it does affect all the parameters of thrombin generation, including the lag-time (which is increased), the endogenous thrombin potential (ETP) and thrombin-peak (both decreased although to a different extent), and the velocity index (decreased). Interestingly, the above effects were more pronounced when the measurements were recorded in the presence of thrombomodulin, thus making the ratio (with/without thrombomodulin) to decrease consistently as a function of the apixaban concentrations. Conclusions These findings support the antithrombotic properties of apixaban and can help to understand the mechanism(s) of action of this drug. Thrombin generation could be used as a convenient laboratory tool to assess the anticoagulant activity of other drugs and to make between-DOAC comparison.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.